Mark Faron, MD
Internal Medicine · Florissant, MONPI 1356314041
Payments from drug & device makers
Across 122 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$293
- AbbVie$256
- Novartis$249
- Pfizer$188
- Novo Nordisk$164
- Johnson & Johnson$105
- plus $687 from 22 others
What the payments were for
- Food & beverage$1,941100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 27 | $293 |
| AbbVie(2 entities) | 13 | $256 |
| Novartis | 12 | $249 |
| Pfizer | 14 | $188 |
| Novo Nordisk | 10 | $164 |
| Johnson & Johnson | 6 | $105 |
| Boehringer Ingelheim | 6 | $87 |
| Abbott | 4 | $81 |
| Astellas Pharma US Inc | 3 | $61 |
| Lilly USA, LLC | 3 | $49 |
| Dexcom, Inc. | 2 | $46 |
| Amgen | 3 | $45 |
| Shire North American Group Inc | 2 | $34 |
| Edwards Lifesciences | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Radius Health, Inc. | 1 | $23 |
| Medtronic | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Bayer | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| GE HealthCare | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Insulet Corporation | 1 | $12 |
| Merck | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,941 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $126,487 |
| JardianceEmpagliflozin | 78 | $73,039 |
| XareltoRivaroxaban | 69 | $69,364 |
| JanuviaSitagliptin Phosphate | 62 | $68,271 |
| OzempicSemaglutide | 43 | $55,680 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 129 | $32,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $30,307 |
| MounjaroTirzepatide | 21 | $22,563 |
| LinzessLinaclotide | 19 | $15,526 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $15,503 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $11,718 |
| FarxigaDapagliflozin Propanediol | 12 | $10,322 |
| Atorvastatin Calcium | 1,364 | $8,078 |
| Arnuity ElliptaFluticasone Furoate | 21 | $6,122 |
| Levothyroxine Sodium | 528 | $5,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $188 | $126,487115 claims |
| GSKArexvy, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $293 | $96,535245 claims |
| Boehringer IngelheimJardiance | $87 | $73,03978 claims |
| Johnson & JohnsonXarelto | $105 | $69,36469 claims |
| MerckJanuvia | $12 | $68,27162 claims |
| Novo NordiskOzempic | $164 | $55,68043 claims |
| Lilly USA, LLCMounjaro | $49 | $22,56321 claims |
| AbbVieLinzess, Synthroid | $256 | $18,06051 claims |
| AstraZenecaFarxiga | $13 | $10,32212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Florissant
- Kim McDonaldFlorissant$206K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.